Project Grant R01CA289268
Award Date
7/1/24
Completion Date
6/30/29
Dollars Obligated
$1M
Federal Agency
National Cancer Institute
Federal Grant Program
93.393
Assistance Type
Project Grant
Place of Performance
Seattle, WA 98195, USA
Similar Awards
The National Cancer Institute awarded a $1,542,555 Project Grant to Sloan-Kettering Institute For Cancer Research under the Cancer Treatment Research program (CFDA 93.395). The grant will fund research from December 2022 through November 2027 to develop more effective treatments for localized bladder cancer. Specifically, the grantee will conduct genomic analyses of bladder cancer patient cohorts to validate DNA damage response mutations as predictors of sensitivity to bacillus Calmette-Guérin...
This Project Grant award from the National Cancer Institute (CFDA 93.396 - Cancer Biology Research) to the Icahn School of Medicine at Mount Sinai provides $684,877 to support a multi-scale analysis of the tumor microenvironment in non-muscle invasive bladder cancer (NMIBC). The goal is to elucidate the cellular, genomic, epigenomic, and spatial features that contribute to resistance to Bacillus Calmette-Guérin (BCG) treatment, which is the standard first-line therapy for high-risk NMIBC. The...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Cause and Prevention Research program (CFDA 93.393), provides $953,982 to The Trustees of Columbia University in the City of New York to investigate mechanisms of tumor plasticity in human bladder cancer. The key objectives are to: 1) analyze the function of the KMT2D histone methyltransferase in modulating luminal-basal plasticity and drug response in bladder cancer; 2) identify chromatin states...
This $514,582 five-year project grant awarded by the National Cancer Institute (NCI) under the Cancer Cause and Prevention Research (CFDA 93.393) program will support research by the University of North Carolina at Chapel Hill (UNC-CH) on the role of APOBEC3 enzymes in bladder cancer initiation, progression, and treatment resistance. The project aims to gain a better understanding of how APOBEC3 promotes squamous differentiation in bladder tumors and whether targeting the IL1A pathway can...
The National Human Genome Research Institute (NHGRI) awarded a $406,500 Project Grant (CFDA 93.172 - Human Genome Research) to JBS Science Inc. to develop a urine-based liquid biopsy assay for comprehensive genetic characterization of non-muscle-invasive bladder cancer (NMIBC). The project aims to create a bladder cancer-targeted, hybridization-based next-generation sequencing (NGS) assay and data analysis pipeline to distinguish NMIBC from muscle-invasive bladder cancer (MIBC), guide disease...
This federal Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) to the University of Southern California provides $712,735.00 in funding for a research project investigating the synergistic effects of combining an EphrinB2 inhibitor (SEPHB4-HSA) with pembrolizumab immunotherapy in patients with muscle-invasive bladder cancer (MIBC). The project aims to determine the clinical outcomes, pathological complete response rates, and recurrence-free survival...
This federal Project Grant award from the National Cancer Institute (NCI), under the Cancer Detection and Diagnosis Research program (CFDA 93.394), is supporting the development of a multi-omic diagnostic test called BCDX for bladder cancer recurrence. The award of $821,797 will fund a clinical validation study designed to generate the data required for FDA regulatory clearance through the 510(k) pathway. The BCDX test uses advanced nanotechnology to detect 12 different biomarkers, including...
This Project Grant award from the National Cancer Institute (CFDA 93.395 - Cancer Treatment Research) provides $583,973.00 to the Sloan-Kettering Institute for Cancer Research to study the role of EP300 gene mutations in bladder cancer pathogenesis and drug response. The key objectives are to: Investigate how EP300 loss-of-function mutations mediate resistance to the FGFR inhibitor erdafitinib in bladder cancer using patient-derived models. Identify genomic alterations associated with...
This Project Grant award of $1,412,000 from the Defense Health Agency's Military Medical Research and Development program (CFDA 12.420) supports a biorepository and community development project to characterize aggressive urothelial cancer variants. The University of Washington, as the prime awardee, will conduct this research over a period of approximately 4 years, from September 2024 through August 2028. The project aims to expand understanding of aggressive forms of urothelial (bladder)...
This National Cancer Institute (NCI) Cancer Research Manpower (CFDA 93.398) Project Grant award for $210,973 provides funding to Brigham & Women's Hospital Inc., a subsidiary of Partners Healthcare System Incorporated, to conduct research on tumor-associated macrophages and their role in cisplatin resistance in bladder cancer. The research aims to determine the mechanism and effectiveness of targeting tumor-associated macrophages to improve the sensitivity of bladder cancer to combined...